Chayakrit Krittanawong: Precision Anticoagulation in the Cath Lab

Chayakrit Krittanawong/X Chayakrit Krittanawong, The ACC/AHA Joint Committee on Clinical Data Standards at American College of Cardiology, The ACC/AHA Joint Committee on Clinical Data Standards at American Heart Association, Founder of HumanX, shared a post on LinkedIn: 'Precision anticoagulation in the cath lab: What happens when the patient doesn't look like the trial? Following our review of intraprocedural anticoagulation in the cardiac catheterization laboratory: Part 1, I'm excited to share Part 2, focusing on patients who are often left out of the evidence. STEMI after fibrinolysis Mechanical circulatory support Nonagenarians Warfarin and DOAC therapy Cirrhosis Advanced CKD and ESRD Thrombocytopenia The challenge is simple: The patients at highest risk of bleeding and thrombosis are often the patients with the least randomized evidence. An elevated INR in cirrhosis doesn't necessarily mean a patient is 'auto-anticoagulated'. A patient on a DOAC may still need intraprocedural anticoagulation. Impella and ECMO require different anticoagulation strategies. And in ESRD, nonagenarians, and thrombocytopenia, the usual risk scores may not tell the whole story. One-size-fits-all anticoagulation doesn't fit these patients. The future is precision-guided anticoagulation: patient, procedure, device, and real-time risk.' Stay updated with Hemostasis Today.